L1 Technology Package for Diagnosis & Therapy of Ovarian and Endometrial Cancer
L1 is overexpressed in highly malignant carcinomas and human ovarian tumors. The antibody 9.3 has improved anti-tumor capacities by inhibit tumor growth and invasion of tumor cells. Antibody can be also used to determine the L1 level in a patient.
Further information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
